Trial Profile
Efficacy of 500µg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Phase IIb, Proof of Concept Clinical Study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Roflumilast (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms FORTUNA
- 20 Jun 2012 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met according to results published in the Journal of Clinical Endocrinology and Metabolism.
- 20 Jun 2012 Results published in the Journal of Clinical Endocrinology and Metabolism.
- 04 May 2012 Additional locations added as reported by ClinicalTrials.gov record.